[P2-033]: SUVN-502 + DONEPEZIL + MEMANTINE (TRIPLE COMBINATION) REPRESENTS A PROMISING NEW APPROACH FOR SYMPTOMATIC TREATMENT OF ALZHEIMER's DISEASE

2017 ◽  
Vol 13 (7S_Part_12) ◽  
pp. P617-P617 ◽  
Author(s):  
Ramakrishna Nirogi ◽  
Koteshwara Mudigonda ◽  
Jyothsna Ravulu ◽  
Gopinadh Bhyrapuneni ◽  
Vijay Benade ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Symptomatic Treatment ◽  
Triple Combination ◽  
New Approach

scholarly journals Neuropsychological and neuroimaging changes in preclinical Alzheimer's disease

2006 ◽  
Vol 12 (5) ◽  
pp. 707-735 ◽  
Author(s):  
ELIZABETH W. TWAMLEY ◽  
SUSAN A. LEGENDRE ROPACKI ◽  
MARK W. BONDI
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Temporal Lobe ◽  
Functional Neuroimaging ◽  
Neuropsychological Functioning ◽  
Clinical Manifestations ◽  
Symptomatic Treatment ◽  
Cross Sectional ◽  
Preclinical Ad ◽  
Normal Individuals

Alzheimer's disease (AD) is a common, devastating form of dementia. With the advent of promising symptomatic treatment, the importance of recognizing AD at its very earliest stages has increased. We review the extant neuropsychological and neuroimaging literature on preclinical AD, focusing on longitudinal studies of initially nondemented individuals and cross-sectional investigations comparing at-risk with normal individuals. We systematically reviewed 91 studies of neuropsychological functioning, structural neuroimaging, or functional neuroimaging in preclinical AD. The neuropsychological studies indicated that preclinical AD might be characterized by subtle deficits in a broad range of neuropsychological domains, particularly in attention, learning and memory, executive functioning, processing speed, and language. Recent findings from neuroimaging research suggest that volume loss and cerebral blood flow or metabolic changes, particularly in the temporal lobe, may be detected before the onset of dementia. There exist several markers of a preclinical period of AD, in which specific cognitive and biochemical changes precede the clinical manifestations. The preclinical indicators of AD reflect early compromise of generalized brain integrity and temporal lobe functioning in particular. (JINS, 2006,12, 707–735.)

A new approach for Alzheimer's disease treatment through P-gp regulation via ibuprofen

2018 ◽  
Vol 214 (11) ◽  
pp. 1765-1771 ◽  
Author(s):  
Chengxiang Zhang ◽  
Heng Qin ◽  
Rui Zheng ◽  
Yubang Wang ◽  
Ting Yan ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Disease Treatment ◽  
New Approach

Souvenaid®: A new approach to management of early Alzheimer’s disease

2013 ◽  
Vol 18 (3) ◽  
pp. 291-299 ◽  
Author(s):  
C. W. Ritchie ◽  
J. Bajwa ◽  
G. Coleman ◽  
K. Hope ◽  
R. W. Jones ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
New Approach ◽  
Early Alzheimer’S Disease

Detection of Alzheimer’s Disease Electroencephalogram Temporal Events

2013 ◽  
Vol 2 (3) ◽  
pp. 44-61 ◽  
Author(s):  
Pedro Miguel Rodrigues ◽  
Diamantino Rui Freitas ◽  
João Paulo Teixeira
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
The Elderly ◽  
Clinical Settings ◽  
Brain Disorder ◽  
New Approach ◽  
Self Organized ◽  
Available Technology ◽  
Temporal Events ◽  
Electroencephalogram Eeg

Alzheimer’s Disease (AD) is a chronic progressive and irreversible neurodegenerative brain disorder. The aging population has been increasing significantly in recent decades. Therefore, AD will continue to increase because the disease affects mainly the elderly. Its diagnostic accuracy is relatively low, and there is not a biomarker able to detect AD without invasive tests. The electroencephalogram (EEG) test is a widely available technology in clinical settings. It may help diagnosis of brain disorders, once it can be used in patients who have cognitive impairment involving a general decrease in overall brain function or in patients with a located deficit. This study is a new approach to detect EEG temporal events in order to improve the AD diagnosis. For that, K-means and Self-Organized Maps were used, and the results suggested that there are sequences of EEG energy variation that appear more frequently in AD patients than in healthy subjects.

Revealing the mechanistic pathway of cholinergic inhibition of Alzheimer's disease by donepezil: a metadynamics simulation study

2019 ◽  
Vol 21 (25) ◽  
pp. 13578-13589 ◽  
Author(s):  
Shibaji Ghosh ◽  
Kalyanashis Jana ◽  
Bishwajit Ganguly
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Simulation Study ◽  
Acetylcholinesterase Inhibitor ◽  
Symptomatic Treatment ◽  
Mechanistic Pathway

Donepezil, an acetylcholinesterase inhibitor, is an approved drug for the symptomatic treatment of Alzheimer's disease (AD).

scholarly journals The Impact of a Long-Term Rivastigmine and Donepezil Treatment on All-Cause Mortality in Patients With Alzheimer’s Disease

2018 ◽  
Vol 33 (6) ◽  
pp. 385-393 ◽  
Author(s):  
Jakub Kazmierski ◽  
Chaido Messini-Zachou ◽  
Mara Gkioka ◽  
Magda Tsolaki
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cox Regression ◽  
Symptomatic Treatment ◽  
Risk Of Death ◽  
Increased Risk ◽  
Functional Assessments ◽  
The Impact

Cholinesterase inhibitors (ChEIs) are the mainstays of symptomatic treatment of Alzheimer’s disease (AD); however, their efficacy is limited, and their use was associated with deaths in some groups of patients. The aim of the current study was to assess the impact of the long-term use of ChEIs on mortality in patients with AD. This observational, longitudinal study included 1171 adult patients with a diagnosis of AD treated with donepezil or rivastigmine. Each patient was observed for 24 months or until death. The cognitive and functional assessments, the use of ChEIs, memantine, antipsychotics, antidepressants, and anxiolytics were recorded. The total number of deaths at the end of the observational period was 99 (8.45%). The patients who had received rivastigmine treatment were at an increased risk of death in the follow-up period. The higher risk of death in the rivastigmine group remained significant in multivariate Cox regression models.

Sign in / Sign up

Export Citation Format

Share Document